Harvard Bioscience Q2 revenue $23.1M (-20% YoY); GAAP net loss $2.9M

HARVARD BIOSCIENCE INC

2024-Q2 EPS reported -$0.18 revenue$47,609,000

Q2 revenue $23.1M, down 20% from $28.8M; gross margin 57.2% vs 58.0%.
GAAP operating loss $2.1M vs income $0.8M; diluted GAAP EPS -$0.07 vs -$0.02.
Adjusted EBITDA $1.3M (5.5% margin) vs $3.9M (13.6%); adjusted EPS $0.00.
Q2 cash from operations $0.6M vs $5.4M; cost actions expected to save $4M annually.
CEO cites challenging market with recovery delayed to later in second half.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.